The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicogenomic profile and progression patterns in lung squamous cell carcinoma treated with immune checkpoint inhibitors.
 
Lingzhi Hong
No Relationships to Disclose
 
Yanhua Tian
No Relationships to Disclose
 
Maricel Corredor
No Relationships to Disclose
 
Sidi Swift
No Relationships to Disclose
 
Hui Li
No Relationships to Disclose
 
Frank Rojas Alvarez
No Relationships to Disclose
 
Waree Rinsurongkawong
No Relationships to Disclose
 
Elliana Young
No Relationships to Disclose
 
Don Gibbons
Stock and Other Ownership Interests - Exact Sciences; Nektar
Honoraria - IDEOlogy Health
Consulting or Advisory Role - Aktis Oncology; AstraZeneca; Lilly; Menarini; Onconova Therapeutics; Sanofi
Research Funding - Astellas Pharma; AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen; Lilly; Mirati Therapeutics (Inst); NGM Biopharmaceuticals; Ribon Therapeutics; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda
 
Ara Vaporciyan
Travel, Accommodations, Expenses - AstraZeneca
 
J. Jack Lee
Honoraria - AstraZeneca; AstraZeneca
 
Sinchita Roy-Chowdhuri
No Relationships to Disclose
 
Mark Routbort
No Relationships to Disclose
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ABION; Allyst; ArriVent Biopharma; ArriVent Biopharma; AstraZeneca; Aviston; Bayer; Black Diamond Therapeutics; BlossomHill Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Merus; Novartis; PineTree; Regeneron; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Johnson & Johnson/Janssen; Regeneron; Spectrum Pharmaceuticals
 
Yasir Elamin
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Johnson & Johnson/Janssen; Lilly; Nuvation Bio; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
Natalie Vokes
Honoraria - Cardinal Health; Genentech; Guardant Health; HMP; Medlive; OMNI Health Media; OncLive/MJH Life Sciences; PlatformQ Health; Sanofi; Tango Therapeutics; Targeted Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Catalyst Pharmaceuticals; EMD Serono; ImmunityBio; Lilly; OncoCyte; Oncohost; Pfizer; Regeneron; Remedy Health; Sanofi; Sanofi/Regeneron; Summit pharmaceuticals; Tempus; Xencor
Research Funding - Amgen; Bristol Myers Squibb; Circulo; EMD Serono/Merck; IDEAYA Biosciences; Mirati Therapeutics; OncoCyte; Sanofi; Summit Health
Travel, Accommodations, Expenses - Regeneron
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; ALK Positive; ArriVent Biopharma; AstraZeneca; BioNtech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; ModeX Therapeutics; Novartis; Ottimo Pharma; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding classification of EGFR mutations; Patents pending regarding subtyping of SCLC lung cancer.
 
Luisa Maren Solis
No Relationships to Disclose
 
Nicholas Navin
No Relationships to Disclose
 
Jianjun Zhang
Honoraria - BeiGene; CancerNet; Geneplus; Geneplus; Hengrui Medicine; Innovent Biologics; Innovent Biologics; innovent biologics; Origimed; Roche; Roche China; Sino-USA Biomedical Platform; Suzhou Medical Association; Takeda; Varian Medical Systems; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; fortvita biologics; Geneplus; Hunan Cancer Hospital; Johnson & Johnson/Janssen; Novartis
Research Funding - Helius; Merck; Novartis; Summit Therapeutics
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital